STAAR Surgical Surges with EVO Lens Growth | Business and Finance News

STAAR Surgical’s Q2 numbers are flying high—revenue surged 111% YoY to $93.54M, crushing estimates, fueled by explosive EVO Plus lens sales in China and double-digit growth in the U.S. and Europe. The company’s betting big on lens-based procedures over lasers, thanks to reversibility, and is upgrading operations with a new ERP system, a CTO hire, and plans to shift China manufacturing to Switzerland to dodge tariffs. Up next: new lens tech, clinical trials, and a bold push to dominate refractive surgery—despite global headwinds. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fad34df8d1b0eebe